MiNK Therapeutics, Inc. (INKT) NASDAQ

15.73

+0.925(+6.25%)

Updated at September 08 03:02PM

Currency In USD

MiNK Therapeutics, Inc.

Address

149 Fifth Avenue

New York City, NY 10010

United States of America

Phone

212 994 8250

Sector

Healthcare

Industry

Biotechnology

Employees

23

First IPO Date

October 15, 2021

Key Executives

NameTitlePayYear Born
Dr. Jennifer S. Buell Ph.D.President, Chief Executive Officer & Director453,6861975
Ms. Christine M. KlaskinTreasurer and Principal Financial & Accounting Officer29,8221966
Ms. Eleni Chantzoura Ph.D.Director & Head of Discovery0N/A
Dr. Garo H. Armen Ph.D.Executive Chairman01953

Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.